A combined 3D QSAR and pharmacophore-based virtual screening for the identification of potent p38 MAP kinase inhibitors: an in silico approach

[1]  Ravindra G. Kulkarni,et al.  Novel targets for antiinflammatory and antiarthritic agents. , 2006, Current pharmaceutical design.

[2]  C. Dominguez,et al.  p38 MAP kinase inhibitors: many are made, but few are chosen. , 2005, Current opinion in drug discovery & development.

[3]  Robert Newton,et al.  Inhibitors of p38 Mitogen-Activated Protein Kinase , 2003, BioDrugs.

[4]  D. Zaller,et al.  Design and synthesis of potent, orally bioavailable dihydroquinazolinone inhibitors of p38 MAP kinase. , 2003, Bioorganic & medicinal chemistry letters.

[5]  M. Feldmann,et al.  Cytokines and anti-cytokine biologicals in autoimmunity: present and future. , 2002, Cytokine & growth factor reviews.

[6]  Andrew R. Leach,et al.  A comparison of the pharmacophore identification programs: Catalyst, DISCO and GASP , 2002, J. Comput. Aided Mol. Des..

[7]  H. Kubinyi.  Comparative Molecular Field Analysis (CoMFA) , 2002 .

[8]  M. Cobb,et al.  Mitogen-activated protein (MAP) kinase pathways: regulation and physiological functions. , 2001, Endocrine reviews.

[9]  G Klebe,et al.  Three-dimensional quantitative structure-activity relationship analyses using comparative molecular field analysis and comparative molecular similarity indices analysis to elucidate selectivity differences of inhibitors binding to trypsin, thrombin, and factor Xa. , 1999, Journal of medicinal chemistry.

[10]  Ajay N. Jain,et al.  Automatic identification and representation of protein binding sites for molecular docking , 1997, Protein science : a publication of the Protein Society.

[11]  Jiahuai Han,et al.  The primary structure of p38 gamma: a new member of p38 group of MAP kinases. , 1996, Biochemical and biophysical research communications.

[12]  Wei Guo,et al.  Characterization of the Structure and Function of a New Mitogen-activated Protein Kinase (p38β)* , 1996, The Journal of Biological Chemistry.

[13]  Gareth Jones,et al.  A genetic algorithm for flexible molecular overlay and pharmacophore elucidation , 1995, J. Comput. Aided Mol. Des..

[14]  T. Pincus,et al.  Prognostic markers of activity and damage in rheumatoid arthritis: why clinical trials and inception cohort studies indicate more favourable outcomes than studies of patients with established disease. , 1995, British journal of rheumatology.

[15]  Jerry L. Adams,et al.  A protein kinase involved in the regulation of inflammatory cytokine biosynthesis , 1994, Nature.

[16]  G. Klebe,et al.  Molecular similarity indices in a comparative analysis (CoMSIA) of drug molecules to correlate and predict their biological activity. , 1994, Journal of medicinal chemistry.

[17]  G. Klebe.  The use of composite crystal-field environments in molecular recognition and the de novo design of protein ligands. , 1994, Journal of molecular biology.

[18]  E. Keystone,et al.  Restricted cytokine expression in rheumatoid arthritis. , 1993, Arthritis and rheumatism.

[19]  Yvonne C. Martin,et al.  A fast new approach to pharmacophore mapping and its application to dopaminergic and benzodiazepine agonists , 1993, J. Comput. Aided Mol. Des..

[20]  C. Dinarello,et al.  Inflammatory cytokines: interleukin-1 and tumor necrosis factor as effector molecules in autoimmune diseases , 1991, Current Biology.

[21]  Arup K. Ghose,et al.  Atomic physicochemical parameters for three dimensional structure directed quantitative structure-activity relationships. 4. Additional parameters for hydrophobic and dispersive interactions and their application for an automated superposition of certain naturally occurring nucleoside antibiotics , 1989, J. Chem. Inf. Comput. Sci..

[22]  R. Cramer,et al.  Comparative molecular field analysis (CoMFA). 1. Effect of shape on binding of steroids to carrier proteins. , 1988, Journal of the American Chemical Society.

[23]  P. Geladi.  Notes on the history and nature of partial least squares (PLS) modelling , 1988 .

[24]  S. Wold,et al.  The Collinearity Problem in Linear Regression. The Partial Least Squares (PLS) Approach to Generalized Inverses , 1984 .

[25]  S. Wold.  Cross-Validatory Estimation of the Number of Components in Factor and Principal Components Models , 1978 .

[26]  Robert Newton,et al.  Inhibitors of p38 mitogen-activated protein kinase: potential as anti-inflammatory agents in asthma? , 2003, BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy.

[27]  R. Maini,et al.  The Role of Cytokines in Rheumatoid Arthritis , 1996, Journal of the Royal College of Physicians of London.

[28]  T. Pincus.  Long-term outcomes in rheumatoid arthritis. , 1995, British journal of rheumatology.

[29]  D. E. Patterson,et al.  Crossvalidation, Bootstrapping, and Partial Least Squares Compared with Multiple Regression in Conventional QSAR Studies , 1988 .

[30]  P. Willett,et al.  A Comparison of Some Measures for the Determination of Inter‐Molecular Structural Similarity Measures of Inter‐Molecular Structural Similarity , 1986 .